Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Corporate Update (July 2024)
6 slides from Nova Eye Medical's corporate update, Jul 8, 2024
Slide 1: Glaucoma Segment Sales Update for the year ended 30 June 2024
Nova Eye Medical Limited (ASX:EYE) Glaucoma Segment Sales Update for the year ended 30 June 2024 8 July 2024
Slide 2: Highlights
Highlights Segment revenue(1) for the year Revenue (1) from sales Fourth consecutive half-year of ended 30 June 2024 of in the USA of revenue growth in the USA including an increase of US$15.3m US$11.4m 77% (1) (A$ 23.5m(2)) up 37% up 73%(1) on the prior in the second half of FY24 on the prior year.
Slide 3: Glaucoma Segment Sales Summary
Glaucoma Segment Sales Summary • Continuing growth in sales following launch of iTrack Advance in Europe in May 2022 and USA April 2023 • Sales growth driven by 73% sales growth in USA compared with FY23 • Growth investment made in the second half of the year in markets outside the USA are expected
Slide 4: USA Glaucoma Segment Sales
USA Glaucoma Segment Sales • Four consecutive half-year periods of growth in USA . Introduction of iTrack Advance in April 2023 (H2FY23) USA sales and sales growth H1FY23 to H2FY24 and growth on previous half • Revenue growth of 77% in H2FY24 compared with H2FY23 7,000,000 demonstrates surgeon take
Slide 5: Outside the USA
Glaucoma Segment Sales Outside the USA • Sales in FY24 in markets outside the USA were in line with FY23. Sales by Territory (excl USA) H1FY24 to H2FY24 1.00 • Following significant sales in the USA, the Company made 0.90 investments during H2FY24 to exploit opportunities outside the USA in markets
Slide 6: Tom Spurling, Kate Hunt, Mark Flynn
Tom Spurling Kate Hunt Mark Flynn Managing Director Chief Commercial Officer Investor Relations M: +61 417 818 658 M: +61 404 080 679 M: +61 416 068 733 E: tspurling@nova-eye.com E: khunt@nova-eye.com E: tspurling@nova-eye.com